¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ÀûÀÀÁõº°, ¹ÙÀÌ¿À¸¶Ä¿º°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹® ¿¹Ãø(2024-2030³â)
Pediatric Cancer Biomarkers Market Size, Share & Trends Analysis Report By Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma), By Biomarker (Alpha-fetoprotein, Neuron-specific enolase), By End Use, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1571424
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 14¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2030³â CAGR 8.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

2023³â 2¿ù NIH º¸°í¼­¿¡ µû¸£¸é Àü ¼¼°è¿¡¼­ ¸Å³â ¾à 40¸¸ ¸íÀÇ 0-19¼¼ ¾î¸°ÀÌ¿Í Ã»¼Ò³âÀÌ ¾Ï Áø´ÜÀ» ¹Þ°í ÀÖÀ¸¸ç, ¸Å³â ¾à 40¸¸ ¸íÀÇ ¾î¸°ÀÌ¿Í Ã»¼Ò³âÀÌ ¾Ï Áø´ÜÀ» ¹Þ°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¼Ò¾Æ¾ÏÀº ¼ºÀÎ ¾Ï°ú ´Þ¸® ¹éÇ÷º´ÀÌ °¡Àå ¸¹À¸¸ç ÁßÃ߽Űæ°è(CNS) Á¾¾ç°ú ¸²ÇÁÁ¾ÀÌ ±× µÚ¸¦ ÀÕ½À´Ï´Ù. ¿©·¯ ÀÇ·á ±â°ü¿¡ µû¸£¸é ¼Ò¾Æ¾ÏÀº ¼ºÀÎ ¾Ïº¸´Ù µå¹°Áö¸¸, Áø´Ü ±â¼úÀÇ Çâ»ó°ú ÀÎ½Ä Áõ°¡·Î ÀÎÇØ Áø´Ü ±âȸ°¡ Áõ°¡Çϰí ÀÖ´Ù°í ÇÕ´Ï´Ù.

¼Ò¾Æ¾ÏÀÇ Á¶±â ¹ß°ß°ú Ä¡·á¸¦ ÃËÁøÇÏ´Â »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¹ß°ßÇϱâ À§ÇØ ¸¹Àº ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 6¿ù, Çʶóµ¨ÇÇ¾Æ ¾Æµ¿º´¿ø(CHOP) ¿¬±¸ÁøÀº »õ·Î¿î ¸é¿ª ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¹ß°ßÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ À¯¸ÁÇÑ ¹ÙÀÌ¿À¸¶Ä¿´Â ³­¼Ò¾ÏÀÇ Á¶±â ¹ß°ß¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç, ³­¼Ò¾ÏÀÌ ÀϹÝÀûÀ¸·Î ³ªÅ¸³ª´Â 2-4³â Àü¿¡ ¹ß°ßÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ¼Ò¾Æ¿Ü°úÇÐÀÇ Ä¡·á ¼º°ú¿Í »ýÁ¸À²À» Çâ»ó½ÃŰ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿¬±¸°¡ Çõ½ÅÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °è¼Ó ¸¸µé¾î³»¸é¼­ ½ÃÀåÀÌ È®´ëµÇ°í ÷´Ü Áø´Ü Åø °³¹ß¿¡ ´ëÇÑ ÅõÀÚ¿Í ÁýÁßµµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´ÜÀ» Áö¿øÇÒ »Ó¸¸ ¾Æ´Ï¶ó Àüü ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ Çаè, ¿¬±¸±â°ü, Á¦¾à»ç °£ÀÇ Çù·ÂÀº ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °øµ¿ ¿¬±¸¿Í ÆÄÆ®³Ê½ÊÀº Àü¹® Áö½Ä°ú ÀÚ¿øÀ» °øÀ¯ÇÔÀ¸·Î½á »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¹ß ¹× °ËÁõÀ» ÃËÁøÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ·£ÅÏÆÄ¸¶´Â 2022³â 2¿ù ÅØ»ç½º´ëÇб³ º¸°Ç°úÇм¾ÅÍ(University of Texas Health Science Center)ÀÇ The Greehey Children Cancer Research Institute¿ÍÀÇ Á¦ÈÞ¸¦ ÅëÇØ ¼Ò¾Æ¾Ï ºÐ¾ß·ÎÀÇ Ãß°¡ ÁøÃâÀ» ¹ßÇ¥Çß½À´Ï´Ù. ¿¬±¸ ¹× °ø°ø-¹Î°£ ÆÄÆ®³Ê½ÊÀº ÷´Ü ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ß°ú »ó¿ëÈ­¸¦ °¡¼ÓÈ­ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÆÄÆ®³Ê½ÊÀº ¿¬±¸°³¹ß °úÁ¤ÀÇ È¿À²¼ºÀ» ³ôÀÌ°í »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿¸¦ º¸´Ù ½Å¼ÓÇϰí È¿°úÀûÀ¸·Î ½ÃÀå¿¡ Ãâ½ÃÇÏ¿© ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù.

¶ÇÇÑ ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀº ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í °³¼±ÀÔ´Ï´Ù. ´Ù¾çÇÑ Áö¿ªÀÇ ÀÇ·á ½Ã½ºÅÛÀÌ ¹ßÀüÇϰí Çö´ëÈ­µÊ¿¡ µû¶ó ÷´Ü Áø´Ü ±â¼ú ¹× ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã¼³ ¹× ¼­ºñ½º °³¼±Àº ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±¤¹üÀ§ÇÏ°Ô µµÀÔÇÏ¿© Áø´Ü Á¤È®µµ ¹× Ä¡·á È¿°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¸°í¼­ - ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÀûÀÀÁõ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¹ÙÀÌ¿À¸¶Ä¿ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ¼Ò¾Æ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Pediatric Cancer Biomarkers Market Growth & Trends:

The global pediatric cancer biomarkers market size is anticipated to reach USD 1.45 billion by 2030 and is projected to grow at a CAGR 8.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rise in the number of pediatric cancer cases globally is a major driver for market expansion. According to a February 2023 NIH report, approximately 400,000 children and adolescents aged 0-19 are diagnosed with cancer globally each year. Pediatric cancers are distinct from those in adults, with the most prevalent types being leukemias, followed by central nervous system (CNS) tumors and lymphomas. According to various health organizations, pediatric cancers, while rarer than adult cancers, are increasingly being diagnosed due to better diagnostic technologies and heightened awareness.

Significant research efforts are uncovering novel biomarkers that can enhance early detection and treatment of pediatric cancers. For instance, in June 2024, researchers at the Children's Hospital of Philadelphia (CHOP) announced the discovery of a new immune-based biomarker. This promising biomarker could revolutionize early detection methods, potentially identifying ovarian cancer two to four years before it typically manifests. Such breakthroughs are crucial for improving pediatric oncology treatment outcomes and survival rates. As research continues to yield innovative biomarkers, the market is expanding, with increased investments and focus on developing advanced diagnostic tools. This progress not only supports earlier and more accurate diagnosis but also drives the overall growth of the pediatric cancer biomarkers market.

Additionally, collaboration between academic institutions, research organizations, and pharmaceutical companies drives innovation in the pediatric cancer biomarkers market. Joint research efforts and partnerships facilitate developing and validating new biomarkers through shared expertise and resources. Collaborative initiatives, such as multi-center For instance, in February 2022, Lantern Pharma announced its expansion into additional pediatric cancers through a partnership with The Greehey Children Cancer Research Institute at the University of Texas Health Science Center. studies and public-private partnerships, accelerate the discovery and commercialization of advanced biomarkers. These partnerships enhance the efficiency of research and development processes, contributing to market growth by bringing novel biomarkers to market more rapidly and effectively.

Furthermore, the expansion and improvement of healthcare infrastructure, particularly in emerging markets, are facilitating the growth of the pediatric cancer biomarkers market. As healthcare systems in various regions develop and modernize, there is greater access to advanced diagnostic technologies and biomarker tests. Improved healthcare facilities and services enable the broader implementation of pediatric cancer biomarkers, enhancing diagnostic accuracy and treatment efficacy.

Pediatric Cancer Biomarkers Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Pediatric Cancer Biomarkers Market Variables, Trends & Scope

Chapter 4. Pediatric Cancer Biomarkers Market: Indication Estimates & Trend Analysis

Chapter 5. Pediatric Cancer Biomarkers Market: Biomarker Estimates & Trend Analysis

Chapter 6. Pediatric Cancer Biomarkers Market: End Use Estimates & Trend Analysis

Chapter 7. Pediatric Cancer Biomarkers Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â